263 related articles for article (PubMed ID: 15193400)
1. ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses.
Pearse MJ; Drane D
Vaccine; 2004 Jun; 22(19):2391-5. PubMed ID: 15193400
[TBL] [Abstract][Full Text] [Related]
2. ISCOMATRIX adjuvant for antigen delivery.
Pearse MJ; Drane D
Adv Drug Deliv Rev; 2005 Jan; 57(3):465-74. PubMed ID: 15560952
[TBL] [Abstract][Full Text] [Related]
3. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
4. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.
Vandepapelière P; Rehermann B; Koutsoukos M; Moris P; Garçon N; Wettendorff M; Leroux-Roels G
Vaccine; 2005 Apr; 23(20):2591-601. PubMed ID: 15780441
[TBL] [Abstract][Full Text] [Related]
5. ISCOMs and ISCOMATRIX.
Sun HX; Xie Y; Ye YP
Vaccine; 2009 Jul; 27(33):4388-401. PubMed ID: 19450632
[TBL] [Abstract][Full Text] [Related]
6. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
Drane D; Gittleson C; Boyle J; Maraskovsky E
Expert Rev Vaccines; 2007 Oct; 6(5):761-72. PubMed ID: 17931156
[TBL] [Abstract][Full Text] [Related]
7. Modulation of immune responses with transcutaneously deliverable adjuvants.
Partidos CD; Beignon AS; Briand JP; Muller S
Vaccine; 2004 Jun; 22(19):2385-90. PubMed ID: 15193399
[TBL] [Abstract][Full Text] [Related]
8. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination.
Ma R; Du JL; Huang J; Wu CY
Biochem Biophys Res Commun; 2007 Sep; 361(2):537-42. PubMed ID: 17662694
[TBL] [Abstract][Full Text] [Related]
9. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
[TBL] [Abstract][Full Text] [Related]
10. The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses.
Boyle J; Eastman D; Millar C; Camuglia S; Cox J; Pearse M; Good J; Drane D
Vaccine; 2007 Mar; 25(14):2541-4. PubMed ID: 17240491
[TBL] [Abstract][Full Text] [Related]
11. The use of CpG DNA as a mucosal vaccine adjuvant.
McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
Curr Opin Investig Drugs; 2001 Jan; 2(1):35-9. PubMed ID: 11527008
[TBL] [Abstract][Full Text] [Related]
12. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
[TBL] [Abstract][Full Text] [Related]
13. CpG oligonucleotides induce strong humoral but only weak CD4+ T cell responses to protein antigens in rhesus macaques in vivo.
Hartmann G; Marschner A; Viveros PR; Stahl-Hennig C; Eisenblätter M; Suh YS; Endres S; Tenner-Racz K; Uberla K; Racz P; Steinman RM; Ignatius R
Vaccine; 2005 May; 23(25):3310-7. PubMed ID: 15837237
[TBL] [Abstract][Full Text] [Related]
14. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers.
Drane D; Maraskovsky E; Gibson R; Mitchell S; Barnden M; Moskwa A; Shaw D; Gervase B; Coates S; Houghton M; Basser R
Hum Vaccin; 2009 Mar; 5(3):151-7. PubMed ID: 19246990
[TBL] [Abstract][Full Text] [Related]
15. Association of antigens to ISCOMATRIX adjuvant using metal chelation leads to improved CTL responses.
Malliaros J; Quinn C; Arnold FH; Pearse MJ; Drane DP; Stewart TJ; Macfarlan RI
Vaccine; 2004 Sep; 22(29-30):3968-75. PubMed ID: 15364446
[TBL] [Abstract][Full Text] [Related]
16. Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications.
Datta SK; Cho HJ; Takabayashi K; Horner AA; Raz E
Immunol Rev; 2004 Jun; 199():217-26. PubMed ID: 15233737
[TBL] [Abstract][Full Text] [Related]
17. Lysophosphatidylcholine is a natural adjuvant that initiates cellular immune responses.
Perrin-Cocon L; Agaugué S; Coutant F; Saint-Mézard P; Guironnet-Paquet A; Nicolas JF; André P; Lotteau V
Vaccine; 2006 Feb; 24(9):1254-63. PubMed ID: 16229929
[TBL] [Abstract][Full Text] [Related]
18. Immune modulator adamantylamide dipeptide stimulates efficient major histocompatibility complex class I-restricted responses in mice.
Becker PD; Nörder M; Guzmán CA; Grinstein S
Clin Vaccine Immunol; 2007 May; 14(5):538-43. PubMed ID: 17344349
[TBL] [Abstract][Full Text] [Related]
19. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of humoral and cellular immune responses by monophosphoryl lipid A (MPLA) as an adjuvant to the rabies vaccine in BALB/c mice.
Hu X; Liu R; Zhu N
Immunobiology; 2013 Dec; 218(12):1524-8. PubMed ID: 23816301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
